Impact of renin-angiotensin system inhibitors after revascularization of patients with left main coronary artery disease — Shmuel Chen (2021) | RDL Network
There is a paucity of data regarding the effect of inhibition of the renin-angiotensin system on outcomes after percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). We sought to examine long-term outcomes of patients with left main coronary disease (LMCAD) randomized to PCI with fluoropolymer-based cobalt-chromium everolimus-eluting stents or CABG according to treatment at discharge with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) in the large-scale, multicenter, randomized EXCEL trial.EXCEL randomized 1905 patients with LMCAD of low and intermediate anatomical complexity (visually-assessed SYNTAX score ≤32) to PCI (n = 948) versus CABG (n = 957). Patients were categorized according to whether they were treated with ACEI/ARB at discharge; their outcomes from discharge to 5 years were examined using multivariable logistic regression with an offset for follow-up time.Among 1775 patients discharged alive with known ACEI/ARB treatment status, 896 (50.5%) were treated with one of these agents. Among those treated with ACEI/ARB, the 5-year rate of all-cause death was similar after PCI or CABG (10.7% versus 9.8% respectively, adjOR, 0.94; 95% CI, 0.56-1.57) in contrast to patients not treated with ACEI/ARB (15.0% versus 7.8%, respectively, adjOR, 2.20; 95% CI, 1.32-3.67) (Pinteraction = 0.02). Significant interactions between treatment arm (PCI versus CABG) and ACEI/ARB treatment status were also found for cardiovascular death (Pinteraction = 0.03), ischemia-driven revascularization (Pinteraction = 0.03), target vessel revascularization (Pinteraction = 0.007) and target vessel failure (Pinteraction = 0.0009).In the EXCEL trial, the postdischarge rates of death and revascularization after 5 years were similar after PCI and CABG in patients with LMCAD treated with ACEI/ARB at discharge. In contrast, event rates were higher after PCI versus CABG in those not so treated.
Shmuel Chen, Björn Redfors, Yangbo Liu, Mathias Vrolix, Carlos Macaya, Ori Ben‐Yehuda, A. Pieter Kappetein, Joseph F. Sabik, Patrick W. Serruys, Gregg W. Stone
Jamie Diamond, Mahesh V. Madhavan, Joseph F. Sabik, Patrick W. Serruys, A. Pieter Kappetein, Martin B. Leon, David P. Taggart, Jacques Berland, Marie‐Claude Morice, Bernard J. Gersh, David E. Kandzari, Ovidiu Dressler, Gregg W. Stone
Evan Shlofmitz, Philippe Généreux, Shmuel Chen, Ovidiu Dressler, Ori Ben‐Yehuda, Marie-Claude Morice, John D. Puskas, David P. Taggart, David E. Kandzari, Aaron Crowley, Björn Redfors, Ghazaleh Mehdipoor, A. Pieter Kappetein, Joseph F. Sabik, Patrick W. Serruys, Gregg W. Stone
Ioanna Kosmidou, Bahira Shahim, Ovidiu Dressler, Björn Redfors, Marie‐Claude Morice, John D. Puskas, David E. Kandzari, Dimitri Karmpaliotis, W. Morris Brown, Nicholas Lembo, Adrian Banning, A. Pieter Kappetein, Patrick W. Serruys, Joseph F. Sabik, Gregg W. Stone
Bahira Shahim, Björn Redfors, Shmuel Chen, Marie-Claude Morice, Bernard J. Gersh, John D. Puskas, David E. Kandzari, Béla Merkely, Ferenc Horkay, Aaron Crowley, Patrick W. Serruys, A. Pieter Kappetein, Joseph F. Sabik, Ori Ben‐Yehuda, Gregg W. Stone
Discussion(0)
No comments yet. Be the first to comment.